| Send2Press.com • Today is Sunday, February 12, 2012 | A Member of the Neotrope News Network |  |
 Search Send2Press.com: |
|
|
|
Drugs and Pharmaceuticals Industry News from Send2Press Newswire
News Index for Sunday, February 12, 2012 ACTT(TM) 'Allergy Drops' - Needle Free Allergy Treatment Wed, 08 Feb 2012, 15:54:08 EST — Edited by Debra Tone AUSTIN, Texas, Feb. 8, 2012 (SEND2PRESS NEWSWIRE) -- Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012. Belvidere Pharmacy, Custom Medicine Makers, Moves to New, and Even Better, Home Wed, 01 Feb 2012, 06:57:11 EST — Edited by Debra Tone HIGHLAND PARK, N.J., Feb. 1, 2012 (SEND2PRESS NEWSWIRE) -- 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere's staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists. Reaction Biology Corporation Unveils Largest Kinase Profiling Data Set in Nature Biotechnology Publication Mon, 31 Oct 2011, 03:57:54 EST — Edited by Debra Tone MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC's proprietary HotSpot(SM) technology. Reaction Biology Launches Recombinant Methyltransferase Line Mon, 24 Oct 2011, 14:25:48 EST — Edited by Debra Tone MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC'), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source. Soy Labs and Missouri Plant Science Center in Governor's Spotlight for Innovative and Economic Development Tue, 20 Sep 2011, 06:59:33 EST — Edited by Debra Tone MEXICO, Mo., Sept. 20, 2011 (SEND2PRESS NEWSWIRE) -- Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act (MOSIRA) as part of the Made in Missouri Jobs Package. E'shee Clinical Esthetic Launches White Truffle Radiance Cream - An Extraordinary Skin Anti-oxidant Wed, 03 Aug 2011, 08:59:36 EST — Edited by Liisa Sullivan PHILADELPHIA, Pa. (SEND2PRESS NEWSWIRE) -- E'shee Clinical Esthetic introduces the next step in anti-aging skin care - White Truffle Radiance Cream - an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies, and offers skin the most effective anti-oxidant protection and luxurious brightening action ever experienced in skincare formulation Millennium Administrators, Inc. Has Been Selected by The City of Scranton, Pennsylvania to Provide Benefit Administration for Active Fire and Police Tue, 12 Jul 2011, 18:45:03 EST — Edited by Debra Tone SCHWENKSVILLE, Pa. (SEND2PRESS NEWSWIRE) -- Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services to enhance cost saving initiatives at the City of Scranton. Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA Mon, 28 Feb 2011, 18:53:36 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer. Business & Decision and New Strategies Partner in Order to Bring Industry Leading ERP Solutions to the Pharmaceutical Industry Mon, 03 Jan 2011, 17:30:56 EST — Edited by Debra Tone PHOENIX, Ariz. (SEND2PRESS NEWSWIRE) -- As a part of Business & Decision's ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of 'AX for Pharma' an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization. Hormone Therapy and Breast Cancer: Is There a Connection? Thu, 09 Dec 2010, 12:00:10 EST — Edited by Debra Tone SOMERSET, N.J. (SEND2PRESS NEWSWIRE) -- From the blogosphere to mainstream media, there's been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the October 2010 issue of the Journal of the American Medical Association (JAMA). Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women's health, examine the issue. Belvidere Pharmacy Earns Top Accreditation Honor, Once Again Wed, 17 Nov 2010, 18:09:23 EST — Edited by Debra Tone NORTH PLAINFIELD, N.J. (SEND2PRESS NEWSWIRE) -- For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board's (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007. Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy Mon, 08 Nov 2010, 11:47:57 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company's lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant. CMI Qualitative Research Manager and Ethnographer Laura Winn Johnson to Present at PMRG Institute Tue, 12 Oct 2010, 15:28:46 EST — Edited by Debra Tone ATLANTA, Ga. (SEND2PRESS NEWSWIRE) -- CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, MA on Oct. 24-26, 2010. The theme for this year's conference is 'Navigating Healthcare's Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.' To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that 'Sea of Troubles' Tue, 07 Sep 2010, 20:46:15 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G. Reaction Biology Receives NCI Grant Award for Epigenetic Platform Wed, 11 Aug 2010, 15:54:06 EST — Edited by Debra Tone MALVERN, Pa. (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents Tue, 06 Jul 2010, 16:42:17 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances. Legal and Medical Substance Abuse Treatment Program Makes Headlines Fri, 18 Jun 2010, 17:14:51 EST — Edited by Debra Tone NEW CASTLE, Pa. (SEND2PRESS NEWSWIRE) -- The Signature Hill Substance Abuse Network, a program dedicated to linking the legal system and treatment of substance abuse through the use of Vivitrol(R) injections has garnered acclaim in media outlets. Articles lauding the program have recently cited the Network's approach to eliminating the consumer demand for drugs and alcohol by eliminating cravings with the use of Vivitrol. Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010) Tue, 01 Jun 2010, 12:29:15 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA. Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010) Mon, 24 May 2010, 18:44:14 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the results of the clinical study entitled 'Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer' at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) Mon, 24 May 2010, 13:06:41 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the clinical results of the study entitled 'A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol' at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy Tue, 04 May 2010, 12:06:12 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled 'Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer' (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA. Paws of Life Joins Nationwide Efforts to Screen Dogs for Arthritis Wed, 21 Apr 2010, 12:09:32 EST — Edited by Carly Zander GREENSBORO, N.C. (SEND2PRESS NEWSWIRE) -- Millions of dogs suffer from canine arthritis and their owners often have no idea their beloved pets are in such pain. A new initiative spearheaded by Novartis Animal Health US, Inc. and Hill's Pet Nutrition will combat that disconnect with a goal of screening one million dogs for canine arthritis. The two companies teamed up to launch the 'Million Dog Search,' a nationwide awareness campaign that will also raise thousands of dollars for animal charities, including Paws of Life. Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing Mon, 05 Apr 2010, 13:58:19 EST — Edited by Debra Tone LONDON, U.K. (SEND2PRESS NEWSWIRE) -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results. Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines Tue, 16 Mar 2010, 06:58:47 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe and places Epeius at the forefront of these emerging fields of clinical medicine. Reports Indicate Fluramene to Provide Earlier and Easier Detection of Ocular Surface Disorders Tue, 09 Mar 2010, 13:51:05 EST — Edited by Debra Tone EUGENE, Ore. (SEND2PRESS NEWSWIRE) -- Noble Vision Group, LLC, a research and development organization today announced reports of favorable results for the topical dye formulation, Fluramene(TM), among leading eye care professionals. Fluramene, the proprietary Fluorescein Sodium and Lissamine Green dye combination is a sterile solution packaged in a 15mL bottle with a control tip dropper. The benefits of both dyes have been studied comprehensively and are well reported as diagnostic tools used independent of each other. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California Thu, 18 Feb 2010, 20:53:21 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century. Scientists Rediscover Gene Target for Cancer Therapy - Rexin-G Receives High-tech Validation as Strategic Anti-cancer Agent Tue, 15 Dec 2009, 12:10:59 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies. Epeius Biotechnologies to Partner at BIO Investor Forum Tue, 20 Oct 2009, 13:17:36 EST — Edited by Debra Tone SAN FRANCISCO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved Wed, 14 Oct 2009, 05:59:50 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which included a Phase II efficacy component and examined progressive dose escalations of Rexin-G. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine Mon, 12 Oct 2009, 13:49:28 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers. Former Corporate Whistleblower Mark Whitacre says 'The Informant' Movie is Only Part of the Story Tue, 15 Sep 2009, 07:59:29 EST — Edited by Carly Zander NEW YORK CITY, N.Y. (SEND2PRESS NEWSWIRE) -- As Mark Whitacre, COO of Cypress Systems, Inc., prepares to walk the red carpet on September 15 during the premiere of 'The Informant,' he has something to say: he is NOT the same man who blew the whistle on his employer in the early 1990's, putting him in the spotlight of one of the largest price-fixing schemes in corporate history and ultimately landing him in federal prison for over eight years. Pharmaceutical eMarketing using Social Media: How to Use It Effectively, Meet the Challenges (Regulatory and Others) and Measure Results in Dollar Terms Tue, 08 Sep 2009, 13:22:43 EST — Edited by Debra Tone NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) -- Eularis is announcing the release of its report 'How To Harness The Power Of Social Media In Pharmaceutical eMarketing.' This report puts to rest the issues around 'can't,' and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives. Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology Patented in U.S. and Mexico Wed, 24 Jun 2009, 13:48:07 EST — Edited by Carly Zander FORT LAUDERDALE, Fla. (SEND2PRESS NEWSWIRE) -- Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. and, recently, in Mexico as well. It also has patent protection overseas. Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival Mon, 22 Jun 2009, 12:45:51 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer Wed, 17 Jun 2009, 06:00:17 EST — Edited by Debra Tone SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs. The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers Tue, 09 Jun 2009, 07:59:24 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 Mon, 18 May 2009, 12:45:19 EST — Edited by Carly Zander SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial Thu, 12 Feb 2009, 15:58:45 EST — Edited by Carly Zander SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body. Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer Mon, 19 Jan 2009, 20:32:23 EST — Edited by Carly Zander SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression. Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement Thu, 08 Jan 2009, 07:59:47 EST — Edited by Carly Zander FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) -- The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate Tue, 16 Dec 2008, 11:36:13 EST — Edited by Carly Zander SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic targeting. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma Thu, 20 Nov 2008, 19:28:29 EST — Edited by Debra Tone SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Eularis Analyzes Pre-Launch Brand Planning with New Pharmaceutical Industry Report Mon, 17 Nov 2008, 09:48:13 EST — Edited by Debra Tone NEW YORK, LONDON, TOKYO, Nov. 17 (SEND2PRESS NEWSWIRE) -- In today's environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits - until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. However, recent studies have shown that seven out of ten drugs launched in the last five years have failed to repay their R&D investment. Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan Wed, 29 Oct 2008, 15:11:24 EST — Edited by Carly Zander SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) Wed, 29 Oct 2008, 11:50:00 EST — Edited by Carly Zander FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results - that were announced yesterday - used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com. Targeting Metastatic Cancer from the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery Mon, 06 Oct 2008, 12:14:50 EST — Edited by Carly Zander SAN MARINO, Calif., Oct. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled 'Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,' was published in the October issue of the International Journal of Oncology. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes Tue, 16 Sep 2008, 15:07:49 EST — Edited by Debra Tone NEW YORK, N.Y. and LONDON, U.K., Sept. 16 (SEND2PRESS NEWSWIRE) -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, 'Implementing a pre-launch named patient programme - evidence of increased market share,' provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create. Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal Mon, 15 Sep 2008, 11:06:58 EST — Edited by Carly Zander SAN MARINO, Calif., Sept. 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed. Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma Tue, 08 Jul 2008, 14:42:48 EST — Edited by Carly Zander SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G Thu, 29 May 2008, 13:19:21 EST — Edited by Carly Zander SAN MARINO, Calif., May 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies Wed, 28 May 2008, 01:05:25 EST — Edited by Liisa Sullivan RICHMOND, Texas (SEND2PRESS NEWSWIRE) -- CYNACON / OCuSOFT(R) (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide. Targeted Gene Delivery Signals Cancer Vaccination in Vivo Tue, 27 May 2008, 11:40:00 EST — Edited by Debra Tone SAN MARINO, Calif., May 27 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles bearing a cytocidal cyclin G1 gene and a granulocyte-macrophage colony stimulating factor (GM-CSF) gene, respectively. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008) Thu, 22 May 2008, 12:46:02 EST — Edited by Debra Tone SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer Mon, 19 May 2008, 07:10:36 EST — Edited by Carly Zander SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks. Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference Mon, 12 May 2008, 01:25:00 EST — Edited by Debra Tone TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan. Eularis to Address Making the Right Research Decision for ROI Mon, 21 Apr 2008, 10:49:23 EST — Edited by Carly Zander NEW YORK, N.Y. and LONDON, U.K., April 21 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI - The Link Between Research and Decisions on Bottom Line Return, at 3rd Annual Pharmaceutical Market Research Summit. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity in Metastatic Pancreatic Cancer Mon, 21 Apr 2008, 08:30:26 EST — Edited by Carly Zander SAN MARINO, Calif., April 21 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) Tue, 15 Apr 2008, 01:03:26 EST — Edited by Carly Zander FRESNO, Calif., April 15 (SEND2PRESS NEWSWIRE) -- Chairman and CEO, Paul Willis stated, 'Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations.' Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium known as SelenoExcell(R). Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him Tue, 25 Mar 2008, 02:00:11 EST — Edited by Carly Zander FRESNO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc., a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new east coast office. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo Tue, 25 Mar 2008, 01:05:29 EST — Edited by Carly Zander SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report Wed, 12 Mar 2008, 13:16:18 EST — Edited by Debra Tone NEW YORK, N.Y. and LONDON, U.K., March 12 (SEND2PRESS NEWSWIRE) -- Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, 'Ensuring Profitable Patient Adherence Programs.' MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London Mon, 10 Mar 2008, 12:50:35 EST — Edited by Debra Tone NEW YORK, N.Y. and LONDON, U.K., March 10 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. Losing Weight But Still Have Belly Bulge? Thu, 06 Mar 2008, 12:32:05 EST — Edited by Carly Zander SALT LAKE CITY, Utah, March 6 (SEND2PRESS NEWSWIRE) -- The same diet that's helping you lose weight might actually be causing you to retain figure-destroying belly fat. That 's because dieting is stressful. You worry about what to eat... when to eat... how much to eat. All that worry leads to 'diet stress,' according to the experts at the Carter-Reed Company(TM), the makers of America's most popular 'Belly Fat' pill, Relacore(R) Myo-Med, Tom Brady and STG Media Corp. Team Up to Jump Start Myo-Med's 2008 Advertising Campaign Wed, 05 Mar 2008, 10:28:02 EST — Edited by Carly Zander TEMPE, Ariz., March 5 (SEND2PRESS NEWSWIRE) -- Superbowl quarterback, Tom Brady has agreed to be the face of Myo-Med, for the launch of their 2008 media campaign. BioForce, the makers of Myo-Med, recently appointed STG Media Corp. as their agency of record to assist them in creating brand awareness among athletes and arthritis sufferers nationwide. Recent Studies Suggest Popular 'Diet Pill' Reduces Acne Breakouts Fri, 15 Feb 2008, 09:55:36 EST — Edited by Carly Zander NEW YORK, N.Y. - Feb. 15 (SEND2PRESS NEWSWIRE) -- As crazy as it sounds, recent studies conducted at Stanford and Wake Forest Schools of Medicine suggest there's a connection between stubborn stress-related belly bulge, unsightly acne flare-ups and the so-called 'Belly Fat' pill, Relacore(R)... and that link is stress. Well, now it seems that stress also increases both the frequency and the severity of acne breakouts. While this may be terrible news for millions of us who seem to be stressed-out even on the best of days, it turns out to be great news for the Carter-Reed Company. deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients Fri, 04 Jan 2008, 11:28:55 EST — Edited by Carly Zander AUSTIN, Texas - Jan. 4 (SEND2PRESS NEWSWIRE) -- deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through eScreen, deverus will now provide clients with technology that creates a web-based system that delivers faster drug test results and paperless transactions. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine Tue, 18 Dec 2007, 10:58:09 EST — Edited by Debra Tone SAN MARINO, Calif. - Dec. 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled 'In Vivo Barriers to Gene Delivery' was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G, a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer Mon, 17 Dec 2007, 14:46:32 EST — Edited by Carly Zander SAN MARINO, Calif. - Dec. 17 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers. Developed as a tumor-targeted anticancer agent, that actively seeks out and destroys metastatic cancers, Rexin-G exhibits unprecedented single-agent efficacy. New Report Examines Pharmaceutical Sales Force Effectiveness Tue, 20 Nov 2007, 16:18:41 EST — Edited by Carly Zander LONDON, U.K. and NEW YORK, N.Y. - Nov. 20 (SEND2PRESS NEWSWIRE) -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A. Mon, 05 Nov 2007, 07:37:06 EST — Edited by Carly Zander SAN MARINO, Calif. - Nov. 5 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research Thu, 11 Oct 2007, 20:58:00 EST — Edited by Liisa Sullivan RICHMOND, Texas - Oct. 11 (SEND2PRESS NEWSWIRE) -- OCuSOFT Inc., producer of the popular ocular-lid hygiene products, OCuSOFT(R) Lid Scrub(TM) and OCuSOFT(R) Lid Scrub(TM) PLUS, is responding to a recent advertisement released by Advanced Vision Research (AVR) that was found to be misleading. Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product Mon, 06 Aug 2007, 19:46:00 EST — Edited by Liisa Sullivan RICHMOND, Texas - Aug. 6 (SEND2PRESS NEWSWIRE) -- CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene. U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas - New Clintelligence(R) Alignment Module Advances Global Management Tue, 12 Jun 2007, 18:00:00 EST — Edited by Chris Simmons KENILWORTH, N.J. - June 12 (SEND2PRESS NEWSWIRE) -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics Mon, 04 Jun 2007, 17:38:00 EST — Edited by Carly Zander SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 - documents the histologic features of tumor destruction observed in chemo-resistant cancers. Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma Mon, 04 Jun 2007, 15:53:00 EST — Edited by Chris Simmons SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G. Drug Development Costs Exceed $802 Million: Global Pharmas Use Clintelligence to Do Something About It Wed, 02 May 2007, 19:00:00 EST — Edited by Chris Simmons KENILWORTH, N.J. - May 2, 2007 (SEND2PRESS NEWSWIRE) -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence - 3C Company's Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio. Tired... Distressed... Unhappy? All Natural 'Feel Good' Pill Strikes a Chord with Millions of Women Thu, 26 Apr 2007, 20:44:00 EST — Edited by Carly Zander SALT LAKE CITY, Utah - Apr. 26 (SEND2PRESS NEWSWIRE) -- This provocative opening line from a television commercial for a 'mood elevating' pill has really struck a nerve. If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts (and women themselves) are willing to admit. That's the logical conclusion drawn from the phenomenal reaction women are having to Libutol, 'The Little Yellow Pill That Makes Life Better' from Blackett Pharmacal(TM). Updated: Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G as Treatment for Diverse Metastatic Cancers Wed, 06 Dec 2006, 20:35:00 EST — Edited by Christopher Simmons SAN MARINO, Calif. and TOKYO, Japan - Dec. 6, 2006 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G(TM) in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G(TM) as Treatment for Diverse Metastatic Cancers Wed, 06 Dec 2006, 13:45:00 EST — Edited by Christopher Simmons SAN MARINO, Calif. and TOKYO, Japan - Dec. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006. Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine Wed, 11 Oct 2006, 16:18:00 EST — Edited by Christopher Simmons SAN MARINO, Calif. - Oct. 11 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company's innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM). Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development Tue, 20 Jun 2006, 15:15:00 EST — Edited by Carly Zander MALVERN, Pa. (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot nanoliter screening platform. Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer Mon, 19 Jun 2006, 16:07:00 EST — Edited by Christopher L. Simmons SAN MARINO, CA - June 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies Fri, 07 Apr 2006, 15:40:00 EST — Edited by Christopher Laird Simmons SAN MARINO, CA - Apr. 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila. How to Support a Healthy Immune System During a Flu Pandemic Tue, 10 Jan 2006, 11:09:00 EST — Edited by Carly Zander CALGARY, AB - Jan. 10 (SEND2PRESS NEWSWIRE) -- A global flu pandemic with up to a billion fatalities is coming and humanity is quite unprepared. If vaccines aren't available, what will governments do to keep their citizens alive and healthy so the world economy does not crash? Hyperimmune Egg, the Super Egg, is a food supplement that can 'help the body achieve a balanced immune system' says Dr. Verna Mackey, CEO of Baby Boomer Productions. Head Lice for the Holidays: A Gift that Keeps on Giving! Mon, 12 Dec 2005, 15:06:00 EST — Edited by Carly Zander JAMESVILLE, VA - Dec. 12 (SEND2PRESS NEWSWIRE) -- When family and friends get together for the holidays, the kids may come home with an unexpected gift, warn the head lice experts at Dermedics Laboratories, Jamesville, VA. And this is one gift you can't just return. Ionic Silver Complex Designed for Use in Humans Receives U.S. Patent Tue, 29 Nov 2005, 12:09:00 EST — Edited by Christopher Simmons FORT LAUDERDALE, FL - Nov. 29 (SEND2PRESS NEWSWIRE) -- Invision International Health Solutions, Inc., a pioneer in the field of ionic silver use in humans, recently announced the issuance of a U.S. Patent on its 'Ionic Silver Complex' technology. Heading Off Head Lice Mon, 29 Aug 2005, 20:34:00 EST — Edited by Christopher Simmons JAMESVILLE, VA - August 29 (SEND2PRESS NEWSWIRE) -- A new homeopathic shampoo from Dermedics Laboratories helps stop the spread of head lice, saves kids embarrassment and reduces exposure to toxins. To a child, back to school means a new backpack, a new teacher, and new friends. For parents, it may also mean a new problem: head lice! Getting a note from the teacher warning that head lice are rampant in your child's class - or worse, not getting a note but having your child come home scratching furiously - can be the start of a parental nightmare. Breakthrough New Ergonomic Hand Sanitizer to be Introduced to Nation's Top Hospital Infection Fighters Thu, 07 Apr 2005, 15:42:00 EST — Edited by Christopher Simmons SANTA BARBARA, Calif. -- (SEND2PRESS NEWSWIRE) -- The nation's top hospital infection fighters will be getting a look at a new breakthrough ergonomic hand sanitizer that holds the promise of preventing 20,000 to 50,000 U.S. deaths each year. Sprixx is an alcohol hand sanitizer dispenser that you wear, use on-the-go, and is ergonomically designed to become a second-nature habit in use. Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector Used in Phase I Clinical Trial Wed, 06 Apr 2005, 12:05:00 EST — Edited by Carly Zander LOS ANGELES, Calif. -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corp. announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. Novel Patented Technology Enables Low Cost, Instant Ultraviolet Disinfection for Home and Personal Care Products Mon, 14 Feb 2005, 14:17:00 EST — Edited by Christopher Laird Simmons BOSTON, MA /Send2Press Newswire/ -- Ultraviolet disinfection technology developed for hospital-use now available for a number of home and personal care products such as toothbrushes, pacifiers, drinking cups, knives, cutting boards, etc. reports UVSolutions, LLC (www.uvs-ultraclean.com).
<< prev
next >>
|
Follow Send2Press on Social Sites: 
Latest Send2Press Newswire Stories:
|
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)